MDGL Madrigal Corp: Rasio rega marang prakiraan pendapatan

Volatility in Madrigal Pharmaceuticals (MDGL) shares is driven by a fierce battle for leadership in liver therapy. The forward P/S ratio visualizes these fluctuations, while 6.90 determines the latest valuation metric. AI-driven molecule screening and colossal demand for NASH treatment provide stability. Investors can track expected revenue dynamics, balancing potential growth against the risks of asset impairment.

Madrigal Pharmaceuticals, Inc. - Rasio kapitalisasi marang dodolan sing dikarepake MDGL (periode 09.08.2024 - 15.11.2026)

Ringkesan rincian data analitis madrigalpharma.com (MDGL)

- rega pasar lan target rega analis:

Bagan rega madrigalpharma.com|MDGL - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Nilai pasar Madrigal Pharmaceuticals, Inc.|MDGL - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Madrigal Pharmaceuticals|MDGL - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku madrigalpharma.com|MDGL - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Madrigal Pharmaceuticals|MDGL - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Madrigal Pharmaceuticals Inc|MDGL - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Madrigal Pharmaceuticals|MDGL - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Madrigal Pharmaceuticals|Likuiditas cepet madrigalpharma.com

- rincian asil keuangan lan kelipatan valuasi:

MDGL - Bathi pungkasan|Proyeksi bathi mangsa ngarep Madrigal Pharmaceuticals|MDGL - Periode bali modal bisnis|Pangali Forward P/E Madrigal Corp|MDGL - Rasio rega marang wutah bathi resik|Pangali EV/EBITDA Madrigal Pharmaceuticals|MDGL - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Madrigal Pharmaceuticals|MDGL - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan madrigalpharma.com|MDGL - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Madrigal Pharmaceuticals

- indikator volume dodolan lan pendapatan:

MDGL - Pendapatan tahunan perusahaan|Prakiraan volume dodolan Madrigal Pharma|MDGL - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Madrigal Pharmaceuticals|MDGL - Wutah dodolan YoY (TTM)

Analisis kabeh metrik perusahaan:Madrigal Pharmaceuticals Inc MDGL

Analyzing the forward price-to-sales chart allows for an assessment of the market status of Madrigal Pharmaceuticals (MDGL) as a biopharmaceutical issuer. This ratio correlates current market capitalization with projected annual revenue, revealing the extent to which future cash flows are overvalued. For Madrigal Pharmaceuticals (MDGL), this indicator is sensitive to geopolitical risks affecting international component logistics and patent protection, which determines the company's resilience to potential corrections.

Pesaing Madrigal Pharmaceuticals